Just in case you missed this in AM last evening?
$Corvus Pharmaceuticals(CRVS.US$ Corvus Pharmaceuticals has received FDA Orphan Drug Designation for its drug candidate soquelitinib for the treatment of T-cell lymphoma.
The company expects to begin a Phase 3 registrational study for the product in patients with relapsed peripheral T-cell lymphoma in Q2.
The designation provides certain benefits to drug developers, including seven years market exclusivity if the drug is approved.![]()
The company expects to begin a Phase 3 registrational study for the product in patients with relapsed peripheral T-cell lymphoma in Q2.
The designation provides certain benefits to drug developers, including seven years market exclusivity if the drug is approved.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
